IDEXX Laboratories Stock Forecast for 2023 - 2025 - 2030
Updated on 04/19/2024
IDEXX Laboratories Stock Forecast and Price Target
If the average price target of $600.00 set by distinguished experts for IDEXX Laboratories over the past few weeks is reached this year, there would be a potential upside of approximately 25.58% from the last closing price in April, 2024. This potential increase is based on a high estimate of $675.00 and a low estimate of $400.00. If you want to invest in IDXX stock, you might also want to take a look at how its competitors are doing.
25.58% Upside
IDEXX Laboratories Fair Value Forecast for 2023 - 2025 - 2030
In the last four years, IDEXX Laboratories's Price has decreased from $327.16 to $0.00 – a 100.00% drop! For next year, the 5 analysts predict Fair Value of $625.51, which would mean an increase of 100.00%. Over the next seven years, the pros' prediction is Fair Valueof $1142.13, which would mean a seven-year growth forecast of 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| A005930 Stock Forecast | Samsung Electronics | Outperform |
10
|
₩79.60k | Buy/Sell | ₩92.49k | 25.63% |
| MRK Stock Forecast | Merck | Outperform |
2
|
$125.23 | Buy/Sell | $130.51 | 11.00% |
| ISRG Stock Forecast | Intuitive Surgical | Outperform |
13
|
$372.63 | Buy/Sell | $408.45 | 15.40% |
| ZTS Stock Forecast | Zoetis | Outperform |
18
|
$153.11 | Buy/Sell | $220.47 | 44.67% |
| EW Stock Forecast | Edwards Lifesciences Corp | Outperform |
11
|
$86.45 | Buy/Sell | $91.18 | 12.20% |
IDEXX Laboratories Revenue Forecast for 2023 - 2025 - 2030
In the last three years, IDEXX Laboratories's Revenue has grown, increasing from $2.71B to $3.66B – an increase of 35.26%. For next year, the 5 analysts predict Revenue of $4.38B, which would mean an increase of 19.61%. Over the next seven years, the pros' prediction is Revenueof $6.90B, which would mean a seven-year growth forecast of 88.37%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| WST Stock Forecast | West Pharmaceutical Services | Outperform |
18
|
$377.33 | Buy/Sell | $380.80 | 0.71% |
| RMD Stock Forecast | ResMed Inc | Outperform |
17
|
$177.61 | Buy/Sell | $201.32 | 15.42% |
| 4901 Stock Forecast | FUJIFILM Holdings | Buy |
18
|
¥9.41k | Buy/Sell | ¥10.57k | 9.43% |
.jpg)
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| STE Stock Forecast | STERIS | Outperform |
13
|
$200.81 | Buy/Sell | $238.33 | 18.52% |
| COO Stock Forecast | The Cooper Companies | Outperform |
13
|
$90.41 | Buy/Sell | $391.40 | 21.67% |
| HOLX Stock Forecast | Hologic | Outperform |
8
|
$75.10 | Buy/Sell | $81.06 | 11.85% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| SGSN Stock Forecast | SGS | Hold |
18
|
CHF82.00 | Buy/Sell | CHF86.34 | 9.76% |
| BVI Stock Forecast | Bureau Veritas | Outperform |
18
|
27.20€ | Buy/Sell | 26.96€ | 12.13% |
| TFX Stock Forecast | Teleflex Inc | Hold |
13
|
$207.38 | Buy/Sell | $263.46 | 27.78% |
IDEXX Laboratories EBITDA Forecast for 2023 - 2025 - 2030
In the last three years, IDEXX Laboratories's EBITDA has grown by 53.15%, from $790.52M to $1.21B. For the next year, analysts are expecting EBITDA to reach $1.46B – an increase of 20.75%. Over the next seven years, experts predict that EBITDA will grow by 104.71%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ELAN Stock Forecast | Elanco Animal Health | Outperform |
13
|
$13.57 | Buy/Sell | $14.90 | 32.65% |
| XRAY Stock Forecast | DENTSPLY SIRONA | Outperform |
17
|
$30.44 | Buy/Sell | $36.00 | 22.54% |
| DPH Stock Forecast | Dechra Pharmaceuticals PLC | - |
18
|
£38.66 | Buy/Sell | £39.86 | -100.00% |
IDEXX Laboratories EBIT Forecast for 2023 - 2025 - 2030
In the last three years, IDEXX Laboratories's EBIT has grown from $694.52M to $1.10B – a 57.97% increase. Next year, analysts are expecting EBIT to reach $1.37B – an increase of 25.23%. Over the next seven years, the forecast is for EBIT to grow by 113.19%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| VIRP Stock Forecast | Virbac | Outperform |
18
|
373.00€ | Buy/Sell | 348.34€ | -1.07% |
| PDCO Stock Forecast | Patterson Companies | Hold |
12
|
$25.47 | Buy/Sell | $31.00 | 17.79% |
| APPS Stock Forecast | Applus Services | Outperform |
15
|
11.58€ | Buy/Sell | 10.92€ | -5.01% |
IDEXX Laboratories EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last four years, IDEXX Laboratories's EPS has decreased from $6.70 to $0.00 – a 100.00% drop! For next year, the 5 analysts predict EPS of $12.81, which would mean an increase of 100.00%. Over the next seven years, the pros' prediction is EPSof $23.39, which would mean a seven-year growth forecast of 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| MD Stock Forecast | Pediatrix Medical Group | Hold |
12
|
$8.81 | Buy/Sell | $9.86 | 2.16% |
| OSUR Stock Forecast | OraSure Technologies | Hold |
11
|
$5.25 | Buy/Sell | $7.40 | 38.10% |
| PAHC Stock Forecast | Phibro Animal Health | Underperform |
18
|
$13.04 | Buy/Sell | $12.50 | -19.48% |
.jpg)